Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

The phase 3 COLUMBA study demonstrated noninferiority of subcutaneous daratumumab (DARA SC) to intravenous daratumumab (DARA IV) in relapsed or refractory multiple myeloma. We present a subgroup analysis of Asian patients from COLUMBA. Eligible patients had ≥ 3 prior lines of therapy, including a pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Iida, Shinsuke, Ishikawa, Takayuki, Min, Chang Ki, Kim, Kihyun, Yeh, Su Peng, Usmani, Saad Z., Mateos, Maria-Victoria, Nahi, Hareth, Heuck, Christoph, Qin, Xiang, Parasrampuria, Dolly A., Gries, Katharine S., Qi, Ming, Bahlis, Nizar, Ito, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960612/
https://www.ncbi.nlm.nih.gov/pubmed/33599794
http://dx.doi.org/10.1007/s00277-021-04405-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960612/
https://www.ncbi.nlm.nih.gov/pubmed/33599794
http://dx.doi.org/10.1007/s00277-021-04405-2

Ejemplares similares